94 related articles for article (PubMed ID: 19110596)
1. Mechanisms of stimulation of granulocytopoiesis with neupogen in patients with breast cancer during chemotherapy.
Khrichkova TY; Gol'dberg VE; Zhdanov VV; Matyash MG; Vysotckaya VV; Simolina EI; Shatalova VA; Popova NO; Miroshnichenko LA; Dygai AM
Bull Exp Biol Med; 2008 Apr; 145(4):467-71. PubMed ID: 19110596
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of Granulocytopoiesis Recovery Stimulation with Filgrastim in Breast Cancer Patients Receiving Chemotherapy.
Goldberg VE; Polyakova TY; Popova NO; Vysotskaya VV; Simolina EI; Dudnikova EA; Goncharova NM; Belevich YV; Tuzikova TP; Goldberg AV; Miroshnichenko LA; Udut EV; Simanina EV; Zyuz'kov GN; Zhdanov VV; Dygai AM
Bull Exp Biol Med; 2018 Nov; 166(1):63-68. PubMed ID: 30450524
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of granulocytopoiesis-stimulating activity of immobilized granulocytic colony-stimulating factor in cytostatic myelosuppression.
Dygai AM; Vereshchagin EI; Zhdanov VV; Zyuz'kov GN; Ermakova NN; Madonov PG; Miroshnichenko LA; Minakova MY; Simanina EV; Stavrova LA; Udut EV; Firsova TV; Khrichkova TY
Bull Exp Biol Med; 2009 Jul; 148(1):49-53. PubMed ID: 19902095
[TBL] [Abstract][Full Text] [Related]
4. Reactions of granulocytic lineage of hemopoiesis and mechanisms of their development in combined treatment with adriablastin and taxotere.
Gol'dberg VE; Khrichkova TY; Shatalova VA; Popova NO; Burshtein ES; Minakova MY; Zhdanov VV; Dygai AM
Bull Exp Biol Med; 2011 Apr; 150(6):718-24. PubMed ID: 22235426
[TBL] [Abstract][Full Text] [Related]
5. XM02 is superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy.
del Giglio A; Eniu A; Ganea-Motan D; Topuzov E; Lubenau H
BMC Cancer; 2008 Nov; 8():332. PubMed ID: 19014494
[TBL] [Abstract][Full Text] [Related]
6. Use of doxorubicin plus cyclophosphamide followed by docetaxel as adjuvant chemotherapy for breast cancer.
Livi L; Meattini I; de Luca Cardillo C; Scotti V; Agresti B; Franzese C; Sanchez L; Nori J; Bertocci S; Cassani S; Bianchi S; Cataliotti L; Biti G
J Chemother; 2011 Feb; 23(1):36-9. PubMed ID: 21482493
[TBL] [Abstract][Full Text] [Related]
7. Responses of Blood System to Doxorubicin/Docetaxel Chemotherapy in Patients with Breast Cancer.
Goldberg VE; Polyakova TY; Popova NO; Vysotskaya VV; Simolina EI; Dudnikova EA; Goncharova NM; Belevich YV; Grigor'ev EG; Goldberg AV; Dygai AM
Bull Exp Biol Med; 2019 Dec; 168(2):275-279. PubMed ID: 31782001
[TBL] [Abstract][Full Text] [Related]
8. Development of a new G-CSF product based on biosimilarity assessment.
Gascon P; Fuhr U; Sörgel F; Kinzig-Schippers M; Makhson A; Balser S; Einmahl S; Muenzberg M
Ann Oncol; 2010 Jul; 21(7):1419-1429. PubMed ID: 20019087
[TBL] [Abstract][Full Text] [Related]
9. Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial.
Nabholtz JM; Cantin J; Chang J; Guevin R; Patel R; Tkaczuk K; Vodvarka P; Lindsay MA; Reese D; Riva A; Mackey J
Clin Breast Cancer; 2002 Oct; 3(4):268-75. PubMed ID: 12425755
[TBL] [Abstract][Full Text] [Related]
10. Role of hemopoietic precursors of various classes in the effect of granulocyte colony-stimulating factor on hemopoiesis during cytostatic-induced myelosuppression.
Dygai AM; Skurikhin EG; Pershina OV; Andreeva TV; Khmelevskaya ES; Minakova MJ
Bull Exp Biol Med; 2010 Oct; 149(4):416-20. PubMed ID: 21234432
[TBL] [Abstract][Full Text] [Related]
11. Low-dose filgrastim in patients with breast cancer treated with docetaxel, doxorubicin, and cyclophosphamide.
Ip EJ; Lee-Ma A; Troxell LS; Chan J
Am J Health Syst Pharm; 2008 Aug; 65(16):1552-5. PubMed ID: 18693211
[TBL] [Abstract][Full Text] [Related]
12. Effects of granulocyte colony-stimulating factor and hyaluronidase on the formation of blood system reactions.
Goldberg ED; Dygai AM; Zyuz'kov GN; Zhdanov VV
Bull Exp Biol Med; 2008 Jun; 145(6):682-7. PubMed ID: 19110550
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant docetaxel for node-negative breast cancer.
Venniyoor A
N Engl J Med; 2011 Mar; 364(10):976-7; author reply 977-8. PubMed ID: 21388324
[No Abstract] [Full Text] [Related]
14. Docetaxel/doxorubicin/cyclophosphamide in the treatment of metastatic breast cancer.
Nabholtz JM; Smylie M; Mackey J; Paterson A; Noel D; al-Tweigeri ; Janowska A; Delorme F; Riva A
Oncology (Williston Park); 1997 Jun; 11(6 Suppl 6):25-7. PubMed ID: 9213324
[TBL] [Abstract][Full Text] [Related]
15. Incidence of bone pain in patients with breast cancer treated with lipegfilgrastim or pegfilgrastim: an integrated analysis from phase II and III studies.
Bondarenko IM; Bias P; Buchner A
Support Care Cancer; 2016 Jan; 24(1):267-273. PubMed ID: 26024743
[TBL] [Abstract][Full Text] [Related]
16. Effect of granulocytic colony-stimulating factor on cytostatic-suppressed granulocytopoiesis under conditions of exhausted catecholamine depot.
Dygai AM; Skurikhin EG; Pershina OV; Simanina EV; Minakova MY; Ermakova NN; Firsova TV; Khmelevskay ES
Bull Exp Biol Med; 2009 May; 147(5):609-12. PubMed ID: 19907751
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy-associated treatment burden in breast cancer patients receiving lipegfilgrastim or pegfilgrastim: secondary efficacy data from a phase III study.
Gladkov OA; Buchner A; Bias P; Müller U; Elsässer R
Support Care Cancer; 2016 Jan; 24(1):395-400. PubMed ID: 26092233
[TBL] [Abstract][Full Text] [Related]
18. Prolonged neutropenia after dose-dense chemotherapy with pegfilgrastim.
Ishiguro H; Kitano T; Yoshibayashi H; Toi M; Ueno T; Yasuda H; Yanagihara K; Garbo CL; Fukushima M
Ann Oncol; 2008 May; 19(5):1019; author reply 1019-20. PubMed ID: 18325914
[No Abstract] [Full Text] [Related]
19. Phase II trial of doxorubicin and docetaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: Eastern Cooperative Oncology Group Study E1196.
Sparano JA; O'Neill A; Schaefer PL; Falkson CI; Wood WC
J Clin Oncol; 2000 Jun; 18(12):2369-77. PubMed ID: 10856096
[TBL] [Abstract][Full Text] [Related]
20. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer.
Holmes FA; O'Shaughnessy JA; Vukelja S; Jones SE; Shogan J; Savin M; Glaspy J; Moore M; Meza L; Wiznitzer I; Neumann TA; Hill LR; Liang BC
J Clin Oncol; 2002 Feb; 20(3):727-31. PubMed ID: 11821454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
